Professor Harrison was a stalwart of hepatology. He led the way in the conduct of many clinical trials that recently culminated in the development of the first approved treatment for people with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD), a disease of pandemic proportions.
Here in Oxford, we worked closely with him over the last seven years during which he provided leadership in the set-up and running of the LITMUS Imaging Study, part of the 'Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS)' project. This project is an ambitious and large-scale consortium of over 50 academic, clinical and industry partners, funded by the Innovative Medicines Initiative (at €47 million).
Professor Harrison was a great mentor and a friend to us in the Radcliffe Department of Medicine, and we will miss him dearly. He touched the lives of many, and his legacy will be felt for a long time to come.